Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct;43(5):481-504.
doi: 10.1007/s10928-016-9492-y. Epub 2016 Sep 19.

Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine

Clara Hartmanshenn  1 , Megerle Scherholz  1 , Ioannis P Androulakis  2   3
Affiliations
Review

Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine

Clara Hartmanshenn et al. J Pharmacokinet Pharmacodyn. 2016 Oct.

Abstract

Personalized medicine strives to deliver the 'right drug at the right dose' by considering inter-person variability, one of the causes for therapeutic failure in specialized populations of patients. Physiologically-based pharmacokinetic (PBPK) modeling is a key tool in the advancement of personalized medicine to evaluate complex clinical scenarios, making use of physiological information as well as physicochemical data to simulate various physiological states to predict the distribution of pharmacokinetic responses. The increased dependency on PBPK models to address regulatory questions is aligned with the ability of PBPK models to minimize ethical and technical difficulties associated with pharmacokinetic and toxicology experiments for special patient populations. Subpopulation modeling can be achieved through an iterative and integrative approach using an adopt, adapt, develop, assess, amend, and deliver methodology. PBPK modeling has two valuable applications in personalized medicine: (1) determining the importance of certain subpopulations within a distribution of pharmacokinetic responses for a given drug formulation and (2) establishing the formulation design space needed to attain a targeted drug plasma concentration profile. This review article focuses on model development for physiological differences associated with sex (male vs. female), age (pediatric vs. young adults vs. elderly), disease state (healthy vs. unhealthy), and temporal variation (influence of biological rhythms), connecting them to drug product formulation development within the quality by design framework. Although PBPK modeling has come a long way, there is still a lengthy road before it can be fully accepted by pharmacologists, clinicians, and the broader industry.

Keywords: Age; Circadian; Gender; Inter-patient variability; PBPK modeling; Personalized medicine; Sex; Special populations.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Fig 1
Fig 1
Physiologically-based pharmacokinetics models for special populations within the AAD2 (adopt, adapt, development, assess, amend, deliver) computation methodology, an iterative and integrative approach to model development
See this image and copyright information in PMC

References

    1. Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet. 2013;52(4):225–241. - PubMed
    1. Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015;520(7549):609–611. - PubMed
    1. Lesko LJ, Schmidt S. Individualization of drug therapy: history, present state, and opportunities for the future. Clin Pharmacol Ther. 2012;92(4):458–466. - PubMed
    1. Waldman SA, Terzic A. Patient-centric clinical pharmacology advances the path to personalized medicine. Biomark Med. 2011;5(6):697–700. - PubMed
    1. Redekop WK, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health. 2013;16(6 Suppl):S4–S9. - PubMed

Publication types

Substances

LinkOut - more resources